You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Novel anti-viral agents to treat influenza

    SBC: ALEXANDER BIODISCOVERIES            Topic: NIAID

    DESCRIPTION provided by applicant Yearly influenza epidemics affect about of the worldandapos s population and estimates of annual mortality range from including approximately deaths and hospitalizations in the United States In addition the likelihood of a severe pandemic caused by a newly emergent strain of influenza virus is very high given that three such pandemics were recorded in the th centu ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. BENEFIT

    SBC: BARRON ASSOCIATES, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): The overall goal of this multi-phase SBIR research effort is to develop a handheld fall risk assessment instrument for use by health and elder care providers. Falls occur in up to 30% of those over the age of 65 and upto 40% for people over the age of 80. Falls place each individual at risk for dangerous closed head injury and long bone fractures. The mortality ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Home Gait Assessment System

    SBC: EMPIRICAL TECHNOLOGIES CORPORATION            Topic: NIA

    DESCRIPTION (provided by applicant): Falls among the elderly, one of the most common reasons requiring medical intervention and a contributing factor in 40% of nursing home admissions, are a major health problem. Several studies have identified quantifiable gait markers that appear to distinguish between elderly fallers and non-fallers. These studies have relied on data acquired in gait-laborat ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Supporting Health, Activities, Resources, and Education: The SHARE Program for ea

    SBC: FIT INTERACTIVE, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The SHARE Program: Supporting Health, Activities, Resources, and Education is a seven-session early stage intervention for care dyads (the IWD and a family CG) that takes advantage of a time when the IWD can still discuss the diagnosis and plan for the future. Communication and planning offers preventive short- and long-term benefits:1 1) IWDs feel reassured th ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure, often resulting i death. Granulocyte colony-stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Point-of-Care HIV Antigen/Antibody Diagnostic Device

    SBC: Mbio Diagnostics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): MBio Diagnostics, Inc. proposes to develop a low-cost, point-of-care (POC), HIV-1/2 antigen/antibody combination diagnostic device. The goal is for the Ag/Ab combo system to deliver the performance of laboratory based,4th generation antigen/antibody clinical analyzers, in a POC platform with cost and workflow of the widely used HIV rapid tests. Phase I research ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a human hepatocyte predictive pharmacology and toxicology system.

    SBC: HemoShear Therapeutics, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): There is a critical need to improve the accuracy of preclinical drug efficacy and toxicity screening and testing through the development of human hepatocyte (liver) in vitro culture systems that more effectively mimic the human in vivo environment. HemoShear is a biotechnology research company that utilizes patented methodologies to restore in vivo responsivene ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Fetal Magnetocardiography Using Non-cryogenic Magnetic Field Sensors

    SBC: QUSPIN INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): While the number of diagnostic technologies available for adult applications continues to grow, there remains a paucity of technologies suitable for fetal evaluation. In particular, noninvasive assessment of fetal cardiac electrophysiology has not been routinely possible despite many decades of fetal ECG research. Recently, a number of groups have demonstrated ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a point of care diagnostic to guide efficient usage of blood produ

    SBC: HEMOSONICS            Topic: NHLBI

    DESCRIPTION (provided by applicant): The Problem: Over 60% of the 600,000 patients undergoing cardio-pulmonary bypass (CPB) procedures in the US each year experience excessive bleeding, which requires transfusions of blood products. There are four treatment options available, each corresponding to a specific hemostatic defect: (a) fresh frozen plasma (FFP) to correct the plasma coagulation factors ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government